Skip to main content

Scilex Holding Co

SCLX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001820190

No open-market purchases or sales by Scilex Holding Co insiders were filed in the last 90 days; 73 institutions reported holding it in 13F filings for Q2 2026, worth $5.48M in total; no superinvestor holds it.

Other share classesSCLXW

Q1 2024 vs. Q4 2023

How the institutions holding Scilex Holding Co changed between Q4 2023 and Q1 2024.

All holders in Q1 2024All holders in Q4 2023

13F holders of SCLX: Q4 2023 compared with Q1 2024
MeasureQ4 2023Of which not filed for Q1 2024Q1 2024Change
Holders912102+13
Shares26.2M31.8K28.6M+2.50M (+9.6%)
Value$53.4M$57.7K$45.5M−$7.82M (−14.7%)

2 institutions that held it in Q4 2023 haven't filed for Q1 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (21)

Institutions that held Scilex Holding Co at the end of Q1 2024 but not at the end of Q4 2023.

Sold out (8)

Institutions that held Scilex Holding Co at the end of Q4 2023 and filed for Q1 2024 without it.

Institutions that sold out of SCLX in Q1 2024
InstitutionShares, Q4 2023Value, Q4 2023
Engineers Gate Manager LP153,481$313.1K
Simplex Trading, LLC72,128$147.0K
Belvedere Trading LLC62,712$127.9K
Renaissance Technologies LLC51,398$105.0K
Bank of New York Mellon Corp48,459$98.9K
Mayo Clinic42,303$86.3K
Scientech Research LLC17,882$36.3K
Pacifica Partners Inc.493$572

Not filed for Q1 2024 yet (2)

Institutions that held Scilex Holding Co at the end of Q4 2023 and haven't filed a 13F for Q1 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding SCLX in Q4 2023 that haven't filed for Q1 2024
InstitutionShares, Q4 2023Value, Q4 2023
Focus Financial Network Inc28,257$57.6K
Blue Rock Advisors, LLC3,519$7